Our research expertise on biological mechanisms and pathways has enabled us to develop a pipeline of drug candidates designed to address important unmet clinical needs, including better management of complications related to kidney and cardiovascular diseases, with the goal of improving outcomes for this large population of underserved patients. Our lead candidate tenapanor, is a first-in-class, targeted, small molecule for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities.
Location: United States, California, Fremont
Employees: 51-200
Phone: +1 510-745-1700
Total raised: $82.5M
Founded date: 2007
Investors 2
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Presidio P... | presidiopa... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.02.2022 | - | $27.5M | - |
| 15.05.2014 | - | $25M | - |
| 31.08.2011 | Series B | $30M | - |
Mentions in press and media 24
| Date | Title | Description |
| 04.09.2024 | ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Per... |
| 28.08.2024 | ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class4 action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 20... |
| 21.08.2024 | ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 21, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 202... |
| 12.03.2024 | Ardelyx, Inc. Reports Employment Inducement Grants | WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medi... |
| 12.03.2024 | Ardelyx, Inc. Reports Employment Inducement Grants | - |
| 22.02.2024 | Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong star... |
| 02.03.2023 | Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update | /EIN News/ -- Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New Drug Application expected in early Q2 2023 Company ends Q4 with approximately $123.9 million in cash an... |
| 03.09.2021 | Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | |
| 29.07.2021 | Ardelyx : Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis | FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treat... |
| 29.07.2021 | Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis |
Show more